Medpace (NASDAQ:MEDP) Releases FY 2026 Earnings Guidance

Medpace (NASDAQ:MEDP) issued an update on its FY 2026 earnings guidance on Friday morning. The company provided earnings per share (EPS) guidance of 17.970-18.320 for the period, compared to the consensus estimate of 17.680. The company issued revenue guidance of $2.8 billion-$2.9 billion, compared to the consensus revenue estimate of $2.8 billion.

Analyst Ratings Changes

MEDP has been the topic of several research reports. TD Cowen increased their price target on shares of Medpace from $492.00 to $673.00 and gave the stock a “hold” rating in a report on Friday. Jefferies Financial Group restated a “hold” rating on shares of Medpace in a research note on Monday, September 14th. Leerink Partners set a $620.00 price objective on shares of Medpace in a research note on Thursday, July 23rd. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a $535.00 price objective on shares of Medpace in a report on Thursday, July 23rd. Finally, BMO Capital Markets increased their price objective on shares of Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a research note on Friday, July 24th. Three analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $638.27.

Medpace Stock Up 0.7%

Shares of MEDP traded up $4.65 during mid-day trading on Friday, reaching $658.61. The company had a trading volume of 53,088 shares, compared to its average volume of 331,522. Medpace has a 52-week low of $373.00 and a 52-week high of $684.52. The stock has a market capitalization of $18.38 billion, a P/E ratio of 38.57, a PEG ratio of 2.96 and a beta of 1.18. The stock has a 50 day moving average of $609.84 and a two-hundred day moving average of $536.74.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, October 21st. The company reported $4.84 earnings per share for the quarter, beating the consensus estimate of $4.44 by $0.40. The company had revenue of $716.00 million during the quarter, compared to analysts’ expectations of $714.47 million. Medpace had a return on equity of 104.17% and a net margin of 18.24%. Medpace’s quarterly revenue was up 8.5% on a year-over-year basis. During the same period last year, the business earned $3.86 earnings per share. On average, sell-side analysts expect that Medpace will post 17.54 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO August Troendle sold 21,966 shares of the firm’s stock in a transaction that occurred on Wednesday, September 30th. The shares were sold at an average price of $625.47, for a total transaction of $13,739,074.02. Following the sale, the chief executive officer owned 338,225 shares of the company’s stock, valued at $211,549,590.75. This trade represents a 6.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In the last 90 days, insiders sold 336,140 shares of company stock valued at $208,008,328. Corporate insiders own 20.50% of the company’s stock.

Key Stories Impacting Medpace

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Raised 2026 outlook: Medpace now expects full-year EPS of $17.97–$18.32, above the $17.68 analyst consensus. Revenue guidance of $2.8–$2.9 billion is also at or above expectations. Medpace forecasts 2026 EPS and buyback
• Positive Sentiment: Quarterly results exceeded expectations: Third-quarter EPS was $4.84 versus the $4.44 consensus, while revenue rose 8.5% year over year to $716 million, slightly ahead of forecasts. Net margin was 18.24%. Medpace third-quarter 2026 results
• Positive Sentiment: Demand indicators remained healthy: Third-quarter net new business awards reached $873 million, and ending backlog grew 5.6% year over year to $3.2 billion, supporting future revenue visibility. Medpace three key takeaways
• Positive Sentiment: $1 billion buyback: The new authorization replaces the prior program and signals management confidence while potentially supporting per-share results. Medpace buyback and third-quarter profit
• Neutral Sentiment: Deutsche Bank raised its price target to $650 from $535 but retained a Hold rating, indicating improved fundamentals may already be reflected in the share price. Deutsche Bank Medpace price target
• Negative Sentiment: Investors remain concerned that Medpace is expensive, with commentary suggesting the stock may be about 24% overvalued. Those concerns help explain why the shares decreased even after the earnings beat and raised outlook. Medpace valuation analysis

About Medpace

Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the development process, from early-stage planning and regulatory submissions through clinical trial execution, data management, analysis and reporting.

Medpace’s services include Phase I through Phase IV clinical research, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.